Access to innovative cancer drugs: Divergent outcomes of HTA bodies' appraisals in France, Germany and the United Kingdom impact on the availability of new medicines

被引：0
|
作者：
Hartmann, M. [1 ]
Droeschel, D. [2 ]
Vollmer, L. [2 ]
De Paz, B. [3 ]
Walzer, S. [2 ]
机构：
[1] European Consulting & Contracting Oncol, Clin Regulatory Affairs, Trier, Germany
[2] MArS Market Access & Pricing Strategy GmbH, Hlth Econ, Weil Am Rhein, Germany
[3] Prioritis SAS, Conseil Strategie, Paris, France
来源：
EUROPEAN JOURNAL OF CANCER | 2017年 / 72卷
关键词：
D O I：
10.1016/S0959-8049(17)30459-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
970
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 10 条
  • [1] ACCESS TO MEDICINES IN THE UNITED KINGDOM: A REVIEW OF HTA DECISIONS FOR NEW MEDICINES
    Abbas, N.
    Hasan, S. S.
    Babar, Z. U. D.
    [J]. VALUE IN HEALTH, 2020, 23 : S665 - S665
  • [2] Access divergence to new cancer medicines in the United Kingdom
    Lythgoe, Mark P.
    Blagden, Sarah
    Stanway, Susannah
    Sullivan, Richard
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 207
  • [3] ACCESSIBILITY OF ORPHAN DRUGS IN FRANCE, UNITED KINGDOM AND GERMANY: DIFFERENT APPROACHES WITH REGARD TO HTA AND PRICES
    Grandfils, N.
    Hounkanlin, H.
    Troubat, A.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A457 - A457
  • [4] IMPACT OF MULTI-DRUG RESISTANCE ON HTA ASSESSMENT OF ANTIBIOTICS IN FRANCE, GERMANY, UNITED KINGDOM
    Charafi, N.
    Chen, X.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A677 - A677
  • [5] CANCER DRUGS IN GERMANY: HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY - AN ANALYSIS USING THE PRISMACCESS® DATABASE
    Mayer, F.
    Hodek, J.
    Walzer, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S63 - S64
  • [6] CANCER DRUGS IN EUROPE: A COMPARISON OF HTA PROCESSES AND DECISIONS FOR NEW AND INNOVATIVE ONCOLOGY THERAPIES IN FRANCE, GERMANY AND THE UK-AN ANALYSIS USING THE PRISMACCESS DATABASE
    Droeschel, D.
    Hartmann, M.
    Vollmer, L.
    Walzer, S.
    de Paz, B.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A761 - A761
  • [7] The access to oncology drugs in France, Germany, Italy, Spain, and the United Kingdom: A comparison based on data from 1998 to 2007
    Wilking, N. E.
    Jonsson, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] ANALYSIS OF THE RELATIONSHIP BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) EVALUATION AND REIMBURSED PRICE OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) COMBINATION DRUGS IN EU-3 (FRANCE, GERMANY, UNITED KINGDOM [UK])
    Roxlau, T.
    Batscheider, A.
    Bonduelle, D.
    Greiner, R. A.
    Lukas, M.
    Antoni, B.
    Schwarzhans, J. P.
    [J]. VALUE IN HEALTH, 2019, 22 : S659 - S659
  • [9] HUMANISTIC BURDEN ASSOCIATED WITH CERVICAL CANCER: AN ANALYSIS OF PATIENT-REPORTED OUTCOMES IN THE EUROPEAN UNION FIVE (FRANCE, GERMANY, ITALY, SPAIN, AND UNITED KINGDOM)
    Nwankwo, C.
    Way, N. A.
    Li, V. W.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A252 - A253
  • [10] Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study
    Chouaid, Christos
    Danson, Sarah
    Andreas, Stefan
    Siakpere, Obukohwo
    Benjamin, Laure
    Ehness, Rainer
    Dramard-Goasdoue, Marie-Helene
    Barth, Janina
    Hoffmann, Hans
    Potter, Vanessa
    Barlesi, Fabrice
    Price, Mark
    Chirila, Costel
    Hollis, Kelly
    Sweeney, Carolyn
    Wolowacz, Sorrel
    Kaye, James A.
    Kontoudis, Ilias
    [J]. LUNG CANCER, 2018, 124 : 310 - 316
1